{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T08:05:48Z","timestamp":1777363548668,"version":"3.51.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00259-026-07806-5","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T06:12:29Z","timestamp":1771913549000},"page":"2955-2962","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["[68Ga]Ga-PSMA PET\/CT in active surveillance: From imaging to informed decision-making \u2014 a \u201cWhistling Arrow\u201d perspective"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4050-1972","authenticated-orcid":false,"given":"Levent","family":"Kabasakal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"issue":"2","key":"7806_CR1","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, Eberli D, De Meerleer G, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and local treatment with curative intent. Eur Urol. 2024;86(2):148\u201363. Epub 2024 Apr 13. PMID: 38614820.","journal-title":"Eur Urol"},{"key":"7806_CR2","doi-asserted-by":"publisher","unstructured":"Lam TBL, MacLennan S, Willemse PM, Mason MD, Plass K, Shepherd R, Baanders R, Bangma CH et al. EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). Eur Urol. 2019;76(6):790\u2013813. https:\/\/doi.org\/10.1016\/j.eururo.2019.09.020.","DOI":"10.1016\/j.eururo.2019.09.020"},{"issue":"2","key":"7806_CR3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.eururo.2018.01.017","volume":"74","author":"MR Cooperberg","year":"2018","unstructured":"Cooperberg MR, Brooks JD, Faino AV, Newcomb LF, Kearns JT, Carroll PR, Dash A, Etzioni R, Fabrizio MD, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW, Zheng Y. Refined analysis of prostate-specific antigen kinetics to predict prostate cancer active surveillance outcomes. Eur Urol. 2018;74(2):211\u20137. Epub 2018 Feb 9. PMID: 29433975; PMCID: PMC6263168.","journal-title":"Eur Urol"},{"issue":"1","key":"7806_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.eururo.2024.09.014","volume":"87","author":"RCN van den Bergh","year":"2025","unstructured":"van den Bergh RCN, Schoots IG, Cornford PA, European Association of Urology Prostate Cancer Guidelines Panel. Standard repeat biopsies during active surveillance for prostate cancer: are they necessary in the magnetic resonance imaging era? Eur Urol. 2025;87(1):5\u20137. Epub 2024 Sep 25. PMID: 39327115.","journal-title":"Eur Urol"},{"key":"7806_CR5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.euros.2025.12.008","volume":"83","author":"YJ Yang","year":"2025","unstructured":"Yang YJ, Yang EJ, Nguyen TT, Choi SY. Transperineal versus transrectal prostate biopsy: A systematic review and Meta-analysis of randomized controlled trials across settings with and without magnetic resonance imaging targeting. Eur Urol Open Sci. 2025;83:205\u201318. PMID: 41551330; PMCID: PMC12803996.","journal-title":"Eur Urol Open Sci"},{"issue":"6","key":"7806_CR6","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.eururo.2016.06.007","volume":"70","author":"LP Bokhorst","year":"2016","unstructured":"Bokhorst LP, Valdagni R, Rannikko A, Kakehi Y, Pickles T, Bangma CH, Roobol MJ, PRIAS study group. A decade of active surveillance in the PRIAS study: an update and evaluation of the criteria used to recommend a switch to active treatment. Eur Urol. 2016;70(6):954\u201360. Epub 2016 Jun 19. PMID: 27329565.","journal-title":"Eur Urol"},{"issue":"1","key":"7806_CR7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/MNM.0000000000000942","volume":"40","author":"E Demirci","year":"2019","unstructured":"Demirci E, Kabasakal L, \u201a\u00e2\u00e0\u221a\u00aaahin OE, Akg\u201a\u00e0\u00f6\u00ac\u222bn E, G\u201a\u00e0\u00f6\u00ac\u222bltekin MH, Do\u2206\u00ed\u221a\u00baanca T, Tuna MB, \u201a\u00e0\u00f6\u221a\u00b1bek C, Kili\u201a\u00e0\u00f6\u221a\u00fc M, Esen T, Kural AR. Can SUVmax values of Ga-68-PSMA PET\/CT scan predict the clinically significant prostate cancer? Nucl Med Commun. 2019;40(1):86\u201391. PMID: 30395048; PMCID: PMC6282663.","journal-title":"Nucl Med Commun"},{"issue":"6","key":"7806_CR8","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","volume":"80","author":"L Emmett","year":"2021","unstructured":"Emmett L, Buteau J, Papa N, Moon D, Thompson J, Roberts MJ, Rasiah K, Pattison DA, et al. The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): A prospective multicentre study. Eur Urol. 2021;80(6):682\u20139. Epub 2021 Aug 28. PMID: 34465492.","journal-title":"Eur Urol"},{"issue":"11","key":"7806_CR9","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.2967\/jnumed.121.263448","volume":"63","author":"L Emmett","year":"2022","unstructured":"Emmett L, Papa N, Buteau J, Ho B, Liu V, Roberts M, Thompson J, Moon D. The PRIMARY score: using intraprostatic 68Ga-PSMA PET\/CT patterns to optimize prostate cancer diagnosis. J Nucl Med. 2022;63(11):1644\u201350. https:\/\/doi.org\/10.2967\/jnumed.121.263448. Epub 2022 Mar 17. PMID: 35301240; PMCID: PMC9635676.","journal-title":"J Nucl Med"},{"key":"7806_CR10","doi-asserted-by":"publisher","unstructured":"Ak\u00e7ay K, Beydagi G, Sahin OE, Akyel R, Akg\u00fcn E, Ekmek\u00e7ioglu \u00d6, Alan Sel\u00e7uk N, Toklu T, et al. Improved accuracy and reliability of PRIMARY scoring using delayed [68Ga] Ga-PSMA PET\/CT imaging. Mol Imaging Radionucl Ther. 2025;34(1):1\u20139. https:\/\/doi.org\/10.4274\/mirt.galenos.2025.16023. PMID: 39917984; PMCID: PMC11827525.","DOI":"10.4274\/mirt.galenos.2025.16023"},{"issue":"3","key":"7806_CR11","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.euo.2023.11.008","volume":"7","author":"JP Buteau","year":"2024","unstructured":"Buteau JP, Moon D, Fahey MT, Roberts MJ, Thompson J, Murphy DG, Papa N, Mitchell C, et al. Clinical trial protocol for PRIMARY2: A Multicentre, phase 3, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 positron emission tomography\/Computed tomography in men with negative or equivocal multiparametric magnetic resonance imaging for the diagnosis of clinically significant prostate cancer. Eur Urol Oncol. 2024;7(3):544\u201352. Epub 2023 Dec 6. PMID: 38061976.","journal-title":"Eur Urol Oncol"},{"issue":"Suppl 4","key":"7806_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/bju.16214","volume":"133","author":"D Bagguley","year":"2024","unstructured":"Bagguley D, Harewood L, McKenzie D, Ptasznik G, Ong S, Chengodu T, Woon D, Sim K, Sheldon J, Lawrentschuk N. The CONFIRM trial protocol: the utility of prostate-specific membrane antigen positron emission tomography\/computed tomography in active surveillance for prostate cancer. BJU Int. 2024;133(Suppl 4):27\u201336. https:\/\/doi.org\/10.1111\/bju.16214. Epub 2023 Nov 13. PMID: 37904302.","journal-title":"BJU Int"},{"issue":"4","key":"7806_CR13","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.euo.2025.02.010","volume":"8","author":"J Liu","year":"2025","unstructured":"Liu J, Harewood L, Bagguley D, Dundee P, Mirmilstein G, Murphy DG, Chan Y, Moon D, Kearns P, Satasivam P, Perera M, Woon DTS, Reeves F, Agarwal DK, Peters J, Katz D, Raj M, Eapen R, Sengupta S, Corcoran N, Chengodu T, Ryan A, Sim K, Wang W, Sheldon J, Lawrentschuk N. Early results from the CONFIRM trial: utility of prostate-specific membrane antigen positron emission tomography\/Computed tomography in active surveillance for prostate cancer. Eur Urol Oncol. 2025;8(4):1118\u201325. https:\/\/doi.org\/10.1016\/j.euo.2025.02.010. Epub 2025 May 6. PMID: 40335400.","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"7806_CR14","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s00259-023-06556-y","volume":"51","author":"K Akcay","year":"2024","unstructured":"Akcay K, Kibar A, Sahin OE, Demirbilek M, Beydagi G, Asa S, Aghazada F, Toklu T, et al. Prediction of clinically significant prostate cancer by [68Ga]Ga-PSMA-11 PET\/CT: a potential tool for selecting patients for active surveillance. Eur J Nucl Med Mol Imaging. 2024;51(5):1467\u201375. https:\/\/doi.org\/10.1007\/s00259-023-06556-y. Epub 2023 Dec 19. PMID: 38112777.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7806_CR15","doi-asserted-by":"publisher","unstructured":"DemirciE, Sahin OE, Ocak M, Akovali B, Nematyazar J, Kabasakal L. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET\/CT imaging. Nucl Med Commun. 2016;37(11):1169-79. https:\/\/doi.org\/10.1097\/MNM.0000000000000566","DOI":"10.1097\/MNM.0000000000000566"},{"key":"7806_CR16","doi-asserted-by":"publisher","unstructured":"Kabasakal L, Ak\u00e7ay K, Sel\u00e7uk AN, Beydagi G, Akg\u00fcn E, Akyel R, Toklu T, T\u00fcrkay R, Eski\u00e7orap\u00e7i S, Akkas BE, Elboga U, K\u00f6mek H, \u00d6zdemir E\u00c7, Sahin OE, Kural AR. Istanbul PSMA PET\/CT criteria (IPPC): an imaging-based approach to patient selection for active surveillance. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07645-w. Epub ahead of print. PMID: 41364230.","DOI":"10.1007\/s00259-025-07645-w"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07806-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07806-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07806-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T01:26:10Z","timestamp":1774401970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07806-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7806"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07806-5","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"30 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No need for ethical clearance.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"No patient data is used for this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The author has no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"There is not any patient\u2019s personal data in this manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}